Pavilion Capital and Hansjörg Wyss featured in a series B round for Harvard-founded ReadCoor, whose existing shareholders also include Lilly Asia Ventures.

Fusion Pharmaceuticals has now raised $171m altogether to deliver cancer radiopharmaceuticals based on McMaster University research.

Visa is buying Plaid four months after investing in it, at a price that doubles the financial data technology provider's 2018 valuation.

GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.

The cash-and-share transaction will allow iRobot to exit the telehealth technology developer eight years after it paid $6m for a minority stake.

Canada Pension Plan Investment Board has pledged up to $20m for the Varian Medical and Johnson & Johnson-backed oncology drug developer.

Eli Lilly-backed ReadCoor took its total funding to $50m and will use the funding to commercialise its gene sequencing technology.

GV-backed solid tumour treatment developer Pact Pharma has completed an oversubscribed $75m series C round led by Vida Ventures.

The payment automation software provider, which counts Mastercard and several banks among its investors, has bagged another $130m.

Proceeds from the Telstra Ventures-led series B round will allow Corvus to accelerate insurance technology development and build tools to improve its risk management.